--- title: "PMV Pharmaceuticals (PMVP) news: offering" url: "https://aibio.space/companies/pmv-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PMVP offering news: PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement. PMV Pharmaceuticals, Inc." --- PMVP PMV Pharmaceuticals, Inc. NASDAQ · United States # PMV Pharmaceuticals (PMVP) news PMVP offering news Financings · 2024-11-20 ## [PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement](https://aibio.space/news/pmv-pharmaceuticals-files-200-000-000-shelf-113-792-846-40-atm/) PMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program. ## Latest PMV Pharmaceuticals news We have not published a story on PMV Pharmaceuticals yet. When there is news, it will appear here. ## PMV Pharmaceuticals at a glance - **Ticker**: PMVP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $79.4 million ### Related companies - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [Pliant Therapeutics](https://aibio.space/companies/pliant-therapeutics/) NASDAQ: PLRX - [ADARx Pharmaceuticals](https://aibio.space/companies/adarx-pharmaceuticals/) NASDAQ: ADRX - [Xencor](https://aibio.space/companies/xencor/) NASDAQ: XNCR - [Nascent Biotech](https://aibio.space/companies/nascent-biotech/) OTC: NBIO - [Shattuck Labs](https://aibio.space/companies/shattuck-labs/) NASDAQ: STTK - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB ### Also on NASDAQ - [LENSAR](https://aibio.space/companies/lensar/) LNSR - [NeuroPace](https://aibio.space/companies/neuropace/) NPCE - [IMMUCELL CORP /DE/](https://aibio.space/companies/immucell-de/) ICCC - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) CGEM - [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) BRTX ## PMV Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$69.9 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | [$58.5 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | | Net income (loss) | [-$77.7 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | [-$58.7 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | | Cash from operations | [-$73.6 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | [-$51.3 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | | Cash and equivalents | [$38.0 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350448/) | [$40.9 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | | Short-term investments | [$75.0 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350448/) | [$128.6 million](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.5 million, plus short-term investments of $67.0 million, $79.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PMV Pharmaceuticals Has PMV Pharmaceuticals raised money recently? Our latest story on this, dated Nov 20, 2024: "PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pmv-pharmaceuticals-files-200-000-000-shelf-113-792-846-40-atm/). What is the ticker symbol of PMV Pharmaceuticals? PMV Pharmaceuticals, Inc. trades under the ticker PMVP on NASDAQ. Where is PMV Pharmaceuticals listed? PMV Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of PMV Pharmaceuticals? The SEC Central Index Key (CIK) for PMV Pharmaceuticals, Inc. is 1699382. Its filings are on SEC EDGAR. How many shares does PMV Pharmaceuticals have outstanding? 53,458,058 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is PMV Pharmaceuticals listed under? Our directory records PMV Pharmaceuticals, Inc. under United States. What does PMV Pharmaceuticals do? Our directory classifies PMV Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of PMV Pharmaceuticals? The ISIN recorded for PMV Pharmaceuticals, Inc. is US69353Y1038. Does aibio.space cover PMV Pharmaceuticals? aibio.space lists PMV Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is PMV Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. Is PMV Pharmaceuticals profitable? PMV Pharmaceuticals, Inc. reported a net loss of $77.7 million for the fiscal year ended Dec 31, 2025, and used $73.6 million of cash in operations, per its annual report to the SEC. How much does PMV Pharmaceuticals spend on research and development? $69.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does PMV Pharmaceuticals have? $79.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest PMV Pharmaceuticals (PMVP) stock news? Our latest story on PMV Pharmaceuticals, dated Nov 20, 2024: "PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement". PMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program. [Source](https://aibio.space/news/pmv-pharmaceuticals-files-200-000-000-shelf-113-792-846-40-atm/). What is PMV Pharmaceuticals's market cap? We do not publish live share prices. In its annual report, PMV Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $53.4 million as of Jun 30, 2025. ## Investor discussion: PMV Pharmaceuticals Members talk about PMV Pharmaceuticals (PMVP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PMV Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350448/pmvp-20260630.htm) 2. 2024-11-20 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1699382/000119312524262148/d868133ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PMVP on TradingView](https://www.tradingview.com/symbols/NASDAQ-PMVP/). ## SEC filings and registration - **SEC name**: PMV Pharmaceuticals, Inc. - **CIK**: 1699382 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PMVP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540 - **Phone**: (609) 642-6670 - **Shares outstanding**: 53,458,058 as of 2026-08-14 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526413254/d174662d8k.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526378838/d113784d8k.htm) filed 2026-09-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1699382/000119312526378780/d95425d424b5.htm) filed 2026-09-02 - [424B5](https://www.sec.gov/Archives/edgar/data/1699382/000119312526376860/d95425d424b5.htm) filed 2026-08-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751d8k.htm) filed 2026-08-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350448/pmvp-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-20260814.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/d94814d8k.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001699382), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PMV Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PMVP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PMV Pharmaceuticals, Inc. - **Ticker**: PMVP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US69353Y1038 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PMVP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pmv-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PMV Pharmaceuticals (PMVP) news: offering", 2026-10-31, https://aibio.space/companies/pmv-pharmaceuticals/